Home
Search results “Monitoring for lung cancer”
Monitoring for Recurrence in Lung Cancer
 
03:10
Philippa Cheetham, MD; Leora Horn, MD, MSc; and Kim L. Sandler, MD, consider challenges in monitoring patients for disease recurrence and comment on how advances in the field will help experts better manage lung cancer in the near future. View more at http://curetoday.com/ CURE: Combining science and humanity to make cancer understandable.
Views: 78 curetoday
EGFR liquid biopsies: a step forward in lung cancer monitoring
 
01:46
A liquid biopsy is a simple, non-invasive alternative to surgical biopsies that enables doctors to use a simple blood sample to discover a range of information about a tumour. Traces of the cancer’s DNA in the blood can give clues about which treatments are most likely to work for a specific patient. The test can detect epidermal growth factor receptor (EGFR) gene mutations, which occur in 10-35% of patients with non-small cell lung cancer (NSCLC). To learn more about the role of liquid biopsies in monitoring lung cancer, detecting disease progression and identifying patients likely to respond to tyrosine kinase therapy, visit http://www.roche.com/liquid-biopsy. Subscribe to our YouTube channel now: https://www.youtube.com/user/roche?sub_confirmation=1 Get in touch with us: https://www.roche.com/ https://www.facebook.com/RocheCareers https://www.linkedin.com/company/roche https://twitter.com/roche Roche has been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally. Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. For more information and insights visit: https://www.roche.com/
Views: 1677 Roche
Dr. Husain on Monitoring the Emergence of T790M in Lung Cancer
 
01:41
Hatim Husain, MD, assistant professor of hematology-oncology at The University of California San Diego Moores Cancer Center, discusses his study on monitoring the emergence of EGFR T790M ctDNA in urine from EGFR mutated NSCLC.
Views: 110 OncLiveTV
Monitoring the Emergence of T790M in EGFR-Mutated Lung Cancer
 
02:05
Hatim Husain, MD, assistant professor of Hematology-Oncology at the University of California San Diego Moores Cancer Center, discusses a study monitoring the emergence of T790M in EGFR-mutated non-small cell lung cancer (NSCLC).
Views: 130 Targeted Oncology
Dr. Husain on the Future of Monitoring T790M in Lung Cancer
 
01:00
Hatim Husain, MD, assistant professor of Hematology-Oncology at the University of California San Diego Moores Cancer Center, discusses the future of monitoring the emergence of EGFR T790M circulating tumor DNA in urine from EGFR-mutated non–small cell lung cancer (NSCLC).
Views: 231 OncLiveTV
Advances in Lung Cancer Treatment and Diagnosis from Stanford Health Care
 
01:30:22
Stanford Health Care lung cancer experts discuss changing demographics, risk factors, symptoms, and advances in diagnosis and treatment of lung cancer. Speakers include: Ann Leung, MD, Diagnostic Radiology Billy W. Loo, Jr., MD, PhD, DABR, Thorasic Radiation Oncology Joseph Shrager, MD, Cardiothoracic Surgery Heather Wakelee, MD, Oncology To learn more about lung cancer treatment options at Stanford: https://stanfordhealthcare.org/medical-conditions/cancer/lung-cancer.html Visit: https://stanfordhealthcare.org
CNS Disease in ALK-Positive NSCLC: Monitoring and Systemic vs. Radiation Therapy
 
02:30
Dr. Ross Camidge, University of Colorado, discusses management of CNS progression for ALK-positive NSCLC including monitoring frequency and preferences between systemic and radiation therapy. http://cancergrace.org/lung/2016/04/13/gcvl_lu_cns_disease_alk-positive_nsclc_monitoring_systemic_radiation_therapy/
Small biopsies, big deal: practical approach to lung cancer diagnosis
 
01:04:36
This is one of three lung pathology lectures I gave in July 2017 at the Colorado Society of Clinical Pathologists' annual "Stars in the Mountains" meeting in Vail, Colorado. It addresses a few key areas of diagnostic difficulty for pathologists in the diagnosis of lung cancer using small lung biopsies (core needle biopsies, transbronchial biopsies, endobronchial biopsies)
Views: 1273 Sanjay Mukhopadhyay
Experts report new findings in immunotherapy for lung cancer
 
01:29
Experts report that there are new findings in immunotherapy for lung cancer.
Will Lung Cancer Treatment Affect Other Organs?
 
02:57
Dr. Hanson explains that chemotherapy treatment for lung cancer can often affect other organs, such as the blood organ, bone marrow, and nerves. Patients that undergo treatment through radiation can also expect that organs hit by the radiation could suffer damage. David S. Hanson, MD, FACP: Oftentimes patients under treatment for lung cancer are concerned about the effects their therapy may have on their body and this is entirely appropriate. Patients who receive chemotherapy for lung cancer can expect that there may damage done to other organs. The most common is the blood organ or the bone marrow and that is because the chemotherapy arrest the growth of those cells, which may cause anemia, which is a low grade blood count and can cause weakness and fatigue or low white cell counts, which can predispose a person to infection or low platelet counts, which may predispose to bleeding. For that reason, during the course of treatment, your doctor will be monitoring your blood counts and likely adjusting your chemotherapy should there be major abnormalities that develop. There are other organs that are also at risk for damage during lung cancer treatment. The most common concern are the nerves. The common chemotherapy that works very well for lung cancer can cause numbness and tingling to come in the hands and feet, that this does not occur for all patients but you and your physician will be monitoring carefully for this and probably make adjustments in your treatment should such damage occur. Many times, if that damage is detected early it can be reversed. There are other organs that are at risk for damage from chemotherapy, which include the liver and the kidneys. The doctor will obtain blood test generally to determine whether or not these organs are functioning normally and if they are not, make adjustments in your treatment. The important thing to know is that you and your doctor will be working as a team to look at the side effects of your treatment and make plans about modifying your treatment to respect those side effects that develop. Finally, there are times when patients must have radiation treatment as a part of their lung cancer treatment plan and radiation can do damage to the organs at which it is end. For that reason your radiation oncologist will make a very careful treatment plan, talk with you about what tissues might be at risk for damage and list out for you those things that you and he or she can do to manage those side effects. Commonly, there may be a skin burn that is apparent on the skin and the area that is given radiation. Proper treatment of the skin can control the symptoms from that irritation and make it far less of a difficult thing to manage than if its not attended too properly. David S. Hanson, MD practices oncology and internal medicine in Baton Rouge and Zachary, Louisiana. Dr. Hanson graduated with an MD 27 years ago. This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk.  If you have any concerns about your health, please consult with a physician.
Views: 6333 Best Doctors
Blood tests for identifying and monitoring ALK-positive non-small cell lung cancer
 
01:02
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Niki Karachaliou, MD, from the Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain, discusses the clinical utility of liquid biopsies for the detection of anaplastic lymphoma kinase gene (ALK) rearrangements and fusions in patients with non-small cell lung cancer.
Views: 82 VJOncology
Will Lung Cancer Treatment Affect Other Organs?
 
02:59
Dr. Hanson explains that chemotherapy treatment for lung cancer can often affect other organs, such as the blood organ, bone marrow, and nerves. Patients that undergo treatment through radiation can also expect that organs hit by the radiation could suffer damage. David S. Hanson, MD, FACP: Oftentimes patients under treatment for lung cancer are concerned about the effects their therapy may have on their body and this is entirely appropriate. Patients who receive chemotherapy for lung cancer can expect that there may damage done to other organs. The most common is the blood organ or the bone marrow and that is because the chemotherapy arrest the growth of those cells, which may cause anemia, which is a low grade blood count and can cause weakness and fatigue or low white cell counts, which can predispose a person to infection or low platelet counts, which may predispose to bleeding. For that reason, during the course of treatment, your doctor will be monitoring your blood counts and likely adjusting your chemotherapy should there be major abnormalities that develop. There are other organs that are also at risk for damage during lung cancer treatment. The most common concern are the nerves. The common chemotherapy that works very well for lung cancer can cause numbness and tingling to come in the hands and feet, that this does not occur for all patients but you and your physician will be monitoring carefully for this and probably make adjustments in your treatment should such damage occur. Many times, if that damage is detected early it can be reversed. There are other organs that are at risk for damage from chemotherapy, which include the liver and the kidneys. The doctor will obtain blood test generally to determine whether or not these organs are functioning normally and if they are not, make adjustments in your treatment. The important thing to know is that you and your doctor will be working as a team to look at the side effects of your treatment and make plans about modifying your treatment to respect those side effects that develop. Finally, there are times when patients must have radiation treatment as a part of their lung cancer treatment plan and radiation can do damage to the organs at which it is end. For that reason your radiation oncologist will make a very careful treatment plan, talk with you about what tissues might be at risk for damage and list out for you those things that you and he or she can do to manage those side effects. Commonly, there may be a skin burn that is apparent on the skin and the area that is given radiation. Proper treatment of the skin can control the symptoms from that irritation and make it far less of a difficult thing to manage than if its not attended too properly. David S. Hanson, MD practices oncology and internal medicine in Baton Rouge and Zachary, Louisiana. Dr. Hanson graduated with an MD 27 years ago.
Views: 439 Best Doctors
Tumor Markers in Cancer diagnosis and Monitoring
 
09:47
A substance produced by a tumor or by the host in response to the tumor’s presence & can be detected in blood, body fluids or tissue of the host
Views: 8860 Pathology Simplified
Repeat biopsy in lung cancer patients with EGFR mutation
 
03:34
Neal Navani, MA, MBBS, MRCP, MSc, PhD, University College London, London, UK, explains the need for re-biopsy in non-small cell lung cancer (NSCLC) patients with progressive disease. Approximately 15% of NSCLC patients have tumour-associated EGFR mutations and are usually treated with EGFR Tyrosine Kinase Inhibitors (TKIs) in first-line. However, after 9-12 months, the disease starts to progress again in the majority of patients. Of these patients, those carrying a T790M mutation in the EGFR gene can benefit from treatment with osimertinib (Tagrisso ®), as demonstrated recently in the AURA3 trial. Dr Navani addresses how the T790M mutation can be detected in patients with progressive NSCLC, in order to inform treatment decisions. He discusses ways to test for this mutation: cell-free DNA assays and advanced biopsy techniques. Cell-free DNA assays are performed using blood samples, and therefore, are convenient for patients and relatively fast. However, the test sensitivity is approximately 60-70% and is lower in patients whose disease only progresses within the lungs. In terms of biopsy techniques, two key techniques are used: endobronchial ultrasound (EBUS) and CT-guided biopsies. Dr Navani explains that together, these two techniques allow sampling from virtually anywhere within the thorax in order to obtain tissue to analyse for T790M mutation. Recorded at the 2017 meeting of the British Thoracic Oncology Group (BTOG) in Dublin, Ireland.
Views: 288 VJOncology
Keeping Lung Cancer Under Control: Bob's Immunotherapy Story
 
04:05
When Bob was diagnosed with non-small cell lung cancer (NSCLC), his wife Julia was so devastated that she cried for several months thinking about her life without him. Bob weighed all his options with his oncologist. After trying chemotherapy, Bob found another treatment that would give him hope—immunotherapy. He enrolled in a clinical trial of a treatment that helps T-cells to recognize and attack cancer cells. Six years later, Bob's health is stable and he remains optimistic. Bob and Julia urge others to not give up hope because advances in cancer research are rapidly providing new treatment options. Help us continue to bring hope to patients with cancer and support lifesaving (and extending) cancer research: http://bit.ly/MatchCRI
The role of the blood-brain barrier in lung cancer treatment
 
03:05
Some types of cancer, such as anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC), frequently spread into the brain and central nervous system. A key challenge in treating these brain metastases is the blood-brain barrier, which guards the brain against the entry of certain molecules. Learn why crossing the blood-brain barrier is important in overcoming certain cancers. To learn how to overcome the blood-brain barrier, visit http://www.roche.com/brain_shuttle. For more information on lung cancer, visit http://www.roche.com/lung-cancer. Subscribe to our YouTube channel now: https://www.youtube.com/user/roche?sub_confirmation=1 Get in touch with us: https://www.roche.com/ https://www.facebook.com/RocheCareers https://www.linkedin.com/company/roche https://twitter.com/roche Roche has been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally. Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. For more information and insights visit: https://www.roche.com/
Views: 11752 Roche
Lung Cancer Clinical Trials: Advances in Immunotherapy
 
29:41
NCI’s Dr. Shakun Malik, head of thoracic oncology therapeutics, and Janet Freeman-Daily, lung cancer patient activist and founding member of #LCSM, host a 30-minute Facebook Live event. The event streamed on November 17 at 8:00 pm ET on http://www.Facebook.com/cancer.gov. For more information on lung cancer, go to http://www.cancer.gov/lung
Catching and treating lung cancer early with electromagnetic navigation bronchoscopy
 
02:25
Electromagnetic navigation bronchoscopy (ENB) is helping doctors detect and treat lung cancer in its initial stages. Onalee is now cancer free after four years of monitoring the nodule on her lung that ended up being stage 1 lung cancer. Early intervention makes a big difference in saving lives. According to the American Cancer Society, about 160,000 Americans die of lung cancer every year, making up more than 1/4 of all cancer-related deaths.
Views: 312 Borgess Health
Saving Lives with Lung Cancer Screening
 
01:43
At Roswell Park, our High Risk Lung Cancer Screening Program is designed to detect lung cancer at its earliest, most curable stages by screening and monitoring the people most likely to develop the disease, especially smokers. Learn more at http://www.roswellpark.org/highrisklung.
Views: 66 RPCICancerTalk
Diagnosising Cancer with a PET/CT Scan
 
01:30
A new imaging device that combines both PET and CT scan helps physicians more accurately diagnosis and treat cancer.
Lung cancer: benefits of liquid biopsy
 
02:24
Gustave Roussy presents at ASCO 2017 two studies showing the advantages of liquid biopsy (blood test) to detect genetic mutations in tumoral cells’ DNA in order to target the treatment and to monitor the disease. Prof. Benjamin Besse (Gustave Roussy, France) explanations.
Views: 217 Gustave Roussy
Lung Cancer Screening Program
 
00:21
The Comprehensive Lung Program at Sunrise Hospital & Medical Center’s goal is to diagnose lung cancer in its earliest stage possible. We are committed to educating the community in Las Vegas, Clark County and surrounding communities on the importance of lung cancer screening along with monitoring any incidental findings found on patients imaging studies while a patient at our hospital.
What You Need to Know About Genetic Testing for Lung Cancer
 
07:28
What You Need to Know About Genetic Testing for Lung Cancer. Non-little cell lung tumor (NSCLC) is a term for a condition caused by in excess of one hereditary transformation in the lungs. Testing for these distinctive changes can influence treatment choices and results. Keep perusing to find out about the diverse sorts of NSCLC, and the tests and medications accessible. What are hereditary changes?. Hereditary changes, regardless of whether acquired or obtained, assume a part in the improvement of growth. Numerous transformations engaged with NSCLC have just been distinguished. This has helped analysts create drugs that objective some of those particular changes. Knowing which transformations are driving your growth can give your specialist a thought of how the tumor will carry on. This can help figure out which drugs are well on the way to be compelling. It can likewise recognize capable medications that are probably not going to help in your treatment. This is the reason hereditary testing after a finding of NSCLC is so essential. It customizes your treatment. The quantity of focused medications for NSCLC keeps on developing. We can hope to see more advances as scientists find more about particular hereditary transformations that reason NSCLC to advance. What number of kinds of NSCLC are there?. There are two principle kinds of lung growth: little cell lung malignancy and non-little cell lung disease. Around 80 to 85 percent of all lung malignancies are NSCLC, which can be additionally separated into these subtypes: *Adenocarcinoma begins in youthful cells that emit bodily fluid. This subtype is normally found in external parts of the lung. It has a tendency to happen more frequently in ladies than in men and in more youthful individuals. It's for the most part a moderate developing tumor, making it more discoverable in beginning periods. *Squamous cell carcinomas begin in the level cells that line within the aviation routes in your lungs. This write is probably going to begin close to the principle aviation route amidst the lungs. *Large cell carcinomas can begin anyplace in the lung and can be very forceful. Less normal subtypes incorporate adenosquamous carcinoma and sarcomatoid carcinoma. When you know which sort of NSCLC you have, the subsequent stage is for the most part to decide the particular hereditary changes that may be included. What do I have to think about hereditary tests?. When you had your underlying biopsy, your pathologist was checking for the nearness of tumor. A similar tissue test from your biopsy can for the most part be utilized for hereditary testing. Hereditary tests can screen for several transformations. These are the absolute most regular changes in NSCLC: *EGFR changes happen in around 10 percent of individuals with NSCLC. Roughly 50% of individuals with NSCLC who've never smoked are found to have this hereditary change. *EGFR T790M is a variety in the EGFR protein. *KRAS changes are included around 25 percent of the time. *ALK/EML4-ALK change is found in around 5 percent of individuals with NSCLC. It has a tendency to include more youthful individuals and nonsmokers, or light smokers with adenocarcinoma. Less basic hereditary transformations related with NSCLC include: BRAF. HER2 (ERBB2). *MEK. *MET. *RET. *ROS1. How do these transformations influence treatment?. There are various medications for NSCLC. Since not all NSCLC is the same, treatment must be painstakingly considered. Itemized sub-atomic testing can let you know whether your tumor has specific hereditary changes or proteins. Directed treatments are intended to treat the particular qualities of the tumor. These are some focused on treatments for NSCLC: EGFR: EGFR inhibitors hinder the flag from the EGFR quality that empowers development. These include: *afatinib (Gilotrif). *erlotinib (Tarceva). *gefitinib (Iressa). These are for the most part oral medicines. For cutting edge NSCLC, these medications can be utilized alone or with chemotherapy. At the point when chemotherapy isn't working, these medications can at present be utilized regardless of whether you don't have the EGFR transformation. Necitumumab (Portrazza) is another EGFR inhibitor utilized for cutting edge squamous cell NSCLC. It's given through intravenous (IV) implantation in blend with chemotherapy. All Photos Licensed Under CC Source : www.pexels.com www.pixabay.com www.commons.wikimedia.org
Views: 1483 Natural Habit
What Is A Calcified Granuloma In The Lung?
 
00:47
Granuloma what does it mean? Mayo clinic. Experts consider it to be singularly unhelpful for monitoring a new lung cancer calcified granuloma is mass within the tissues of particular organ, usually lungs, which has. It scared me to death when my doctor sent the last catscan showed a punctate calcified granuloma. They can become calcified over time, as calcium tends to answer (1 of 5) a granuloma is not sign lung cancer more often than they do require any major treatment. I have a spot on my lung the size of quarter. Granuloma what does it mean? Mayo clinic mayoclinic granuloma expert answers faq 20057838 url? Q webcache. Although granulomas due to histoplasmosis are noncancerous (benign), they may resemble cancer on an x ray, especially if haven't calcified. (2014) calcified granulomatous lung lesions contain abundant mycobacterium tuberculosis may 29, 2003 hi im new. Often, a granuloma becomes calcified, citation iida t, uchida k, lokman n, furukawa a, suzuki y, et al. Calcified granuloma in chest x ray, could it be lung cancer? (very calcified lower lobe of right inspiregrace global resource for what is a granuloma? (with pictures). Granulomas eventually become calcified and have the same density as bone, making them more clearly visible on an x ray jan 20, 2011 has done wonderful not had anymore trouble. Googleusercontent search. The cause of inflammation can be fungal, bacterial or parasitic, jun 16, 2012 well, the doctor called me back and said x ray was 'normal,' but that i had a calcified granuloma should get another chest in radiologist noted there 'calcified bottom lobe my right lung. Calcification of the granuloma causes differential considerations a calcified lesion include granuloma, hamartoma, carcinoid, osteosarcoma, chondrosarcoma and lung metastases or because it usually takes some time for calcium to be deposited in is generally assumed that an old area inflammation. Just recently had chest x ray and ct scan show calcified granuloma in lungs liver is normally seen the rarely kidneys or other organs of body. Pulmonary nodules (lung nodules) is calcified granuloma in the lung some form of cancer? Is it a lungs & calcium granulomatous lesions contain abundant granuloma? Possibly cancer? Lung respiratory. The calcified lung nodule what does it mean? Ncbi nih. I went in the er with flu and pneumonia. For example, a calcified granuloma in the lung may be due to tuberculosis contracted years earlier that is now inactive and dormant most common cause of nodule calcification formation, usually response ground glass nodulesby location[ ] show little or no growth for 2 yearscentral granulomas cancer are by far two causes pulmonary sep 16, 2011 nodules caused inflammation. Ask an expert calcified granulomata in lungs netwellness. Medical definition of calcified granuloma medicinenetradiology reference article chest radiology university virginia. What is a lung granuloma? Cancerconnect. Calcification refers to the accumulation of calcium most
Views: 3724 Another Question
Pioneering Lung Cancer Guide to breathing exercises when in a prone position
 
06:19
This video guide has been developed by physiotherapists to make breathing feel easier. It describes exercises to be conducted when you are lying down. The exercises help you to stretch the sides of your ribcage. We offer the videos as something practical to take away from our Pioneering Lung Cancer site. The complete set of videos are featured on the free Lung+ App, which is available on iTunes and Google Play. http://www.pioneeringhealthcare.com/lung-cancer/living-with-lung-cancer/mobile-app/ More Videos from Roche on http://www.youtube.com/user/roche
Views: 1531 Roche
The Basics of a Lung Cancer Workup
 
04:27
Dr. Gerard Silvestri, Medical University of South Carolina, describes the steps necessary to work up a lung cancer diagnosis, from initial scan to choice of treatment. http://cancergrace.org/lung/2016/03/02/gcvl_lu_lung_cancer_workup_basics/
EGFR Testing for NSCLC
 
09:30
Panelists Mark Socinski, MD; Vali Papadimitrakopoulou, MD; Tracey Evans, MD; Alexander Drilon, MD; and Jared Weiss, MD, provide insight on which EGFR mutations to test for in patients with non–small cell lung cancer.
Views: 1464 OncLiveTV
Liquid biopsy in lung cancer: state of the art and future applications-  A.Marchetti
 
27:11
Genomics in Oncology lecture series invites Antonio Marchetti, Professor of Pathology and Director of the Center of Predictive Molecular Medicine at the University of Chieti in Italy. Professor Marchetti presents his research with liquid biopsies in lung cancer and shares his perspective on the future of applying next-generation sequencing technology in plasma to drive the future of personalized medicine. Learn more about Genomics in Oncology, visit our website: http://www.illumina.com/areas-of-interest/cancer/research.html A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. *Data calculations on file. Illumina, Inc., 2015. Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc View customer spotlight videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars https://www.youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina product videos https://www.youtube.com/playlist?list=PLKRu7cmBQlaj6YuZmkfxZcT9twqDgP2Xd View Illumina support videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM
Views: 1021 Illumina
What is Lung Nodule Monitoring and How Can It Help Me?
 
01:31
Dr. Humdum Durrani specializes in oncology and hematology in Fort Smith, Arkansas. Learn more at www.mercy.net/doctor/humdum-pasha-durrani-md.
Views: 35 theMercyChannel
Quitting smoking drastically reduces risk of lung cancer
 
01:49
Quitting not only cuts your cancer risk but if you quit right now, your heart disease and stroke risk goes back to that of a nonsmoker after five years. Subscribe to KOAT on YouTube now for more: http://bit.ly/1jocB9r Get more Albuquerque news: http://koat.com Like us: http://facebook.com/KOAT7 Follow us: http://twitter.com/KOATLiveUpdates Google+: http://plus.google.com/+koat
Views: 174 KOAT
Nurse sings "What a Wonderful World" to patient with metastatic lung cancer
 
02:47
My mom is in the hospital with metastatic lung cancer being serenaded by charge nurse Ace Ibarrola, R.N. "What a Wonderful World" at Pomona Valley Hospital Medical Center 2/23/2015
Views: 8252 Chris Molloy
Strand Life Sciences launches ‘STRAND LB’ - a ground-breaking method for monitoring cancer

Strand
 
02:28
Strand Life Sciences launches ‘STRAND LB’ - a ground-breaking method for monitoring cancer Strand LB helps monitor lung, breast, colorectal and other cancers for tumor presence, response, and recurrence Bangalore, April 11th 2017: According to data from the Indian Council of Medical Research (ICMR), India is projected to have 17.3 lakhs new cases of cancer reported in 2020 and over 8.8 lakhs patients are expected to die from the disease. To counter this large burden and rapid increase in incidence and persistence of the high mortality rate of 50%, there is a strong need for better ways to diagnose, manage, and treat cancer. Strand Life Sciences today announced the launch of their Liquid Biopsy test portfolio ‘STRAND LB’ that provides highly sensitive detection of tumor traces from a simple blood draw. This powerful tool can provide early and precise indication of tumor presence, cancer recurrence, and response to therapy compared to any other method used in the medical industry. Typically, tumors are assessed through invasive tumor biopsies or through radioactive scans. This latest technique allows earlier assessment with minimal discomfort to patients. “Liquid biopsy is a paradigm shift that involves a minimally-invasive procedure, no radioactive scans, and can detect tumor DNA traces from a simple blood draw. However, detecting tumor DNA requires a highly sensitive test capable of detecting 1 molecule in a 1000. Our study on patients spanning a wide variety of cancer types – including lung, colorectal, breast, and bladder cancer - shows that STRAND LB can detect tumor DNA traces in as many as 35% of patients with early-stage cancer, going up to 70-90% in patients with locally advanced or metastatic cancer. These figures are at par with the best in the world”, said Dr. Vijay Chandru, Chairman and Managing Director, Strand Life Sciences. The Strand LB tests are an outcome of the collaboration between Scientific teams of Strand and Mazumdar Shaw Center for Translational Research (MSCTR), who worked together to develop these advanced tests which were validated by clinicians at the Mazumdar Shaw Medical Center (MSMC). These non-invasive Liquid Biopsy tests will advance the field of cancer diagnostics, as they offer ultra-sensitive detection of mutations which will help in early detection and intervention. To reflect the collaboration these tests will be made available and offered to all patients at MSMC. “Innovations like Liquid Biopsy are huge breakthroughs in cancer detection and management. India needs such pioneering innovation in healthcare to foster early detection which can be a great help in bringing down the non-communicable disease (NCD) burden that our country is facing today. I congratulate the scientific teams at Strand and MSCTR as well as doctors at MSMC
Tissue vs liquid biopsy for molecular testing in lung cancer
 
03:13
Fabrice Barlesi explains the problems oncologists face with tissue biopsy for molecular testing in lung cancer and promise of liquid biopsy, in particular plasma and novel urinary techniques. http://www.esmo.org Video produced by the European Society for Medical Oncology (ESMO)
Emerging Biomarkers for Lung Cancer
 
08:34
Panelists Benjamin P. Levy, MD; Marina Garassino, MD; Ramaswamy Govindan, MD; Sarah B. Goldberg, MD, MPH; Mark G. Kris, MD; and Chandra P. Belani, MD, discuss the value of other predictive biomarkers, including mutational burden, in lung cancer.
Views: 222 OncLiveTV
Progression is progression! The importance of monitoring the efficacy of immunotherapy in NSCLC
 
01:26
Recently, due to the revolution of immunotherapy in the treatment of non–small cell lung cancer (NSCLC), more drugs are being licensed to treat patients in the second-line setting. Although overall survival in these patients has been shown to increase, the same can not be said for the rate of progression-free survival. Here, Ross Camidge, MD, PhD, of University of Colorado, Aurora, CO, discusses the importance of carefully monitoring these patients during chemotherapy. This interview was recorded at the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.
Views: 18 VJOncology
Tumor Markers in Lung Cancer - Deborah Mukherji
 
26:22
Paper presented at the Annual Meeting of the Lebanese Pulmonary Society - Mövenpick Hotel - April 24th to 27th, 2013 - Beirut - Lebanon Conférence présentée lors du Congrès annuel de la Société Libanaise de Pneumologie - Hôtel Mövenpick - 24 au 27 avril 2013 - Beyrouth - Liban
Views: 641 slpsleb
A new prognostic test for lung cancer using blood samples instead of biopsies
 
03:52
Laboratory staff have developed and now deliver a clinical service that uses circulating tumour DNA for the detection of biomarkers in a cancer patient's blood sample. This enables the monitoring of a cancer patient in real-time to aid treatment decisions, and avoids invasive and costly surgical procedures. The technology has currently been employed in clinical practice across Wales for lung cancer, and they are also receiving requests for analysis from clinical sites across the UK. The technology may also be applied for other cancer types, for which work is now in progress. The development and validation of this technology from a research tool to a clinical diagnostic service has taken several years and research projects. These have been supported by the Wales Cancer Research Centre, the Stepping Stones Charity, Velindre Charitable Funds and AstraZeneca. Laboratory staff have worked in collaboration with clinical teams and patients across South Wales in the development and roll-out of this new clinical service.
Electronic Nose Can Diagnose Lung Cancer
 
01:41
A new technology called an Electronic Nose may someday change late lung cancer diagnosis. A smell print of the breath is made a computer program matches that smell print with molecules in the breath associated with lung cancer. This allowed doctors to predict who had lung cancer and who did not. The Cleveland Clinic study is in the American Journal of Respiratory and Critical Care Medicine, scientists say much more research must be done, but they found the device accurately predicted late stage lung cancer more than 70% of the time. http://bit.ly/cqWwIg
Views: 4567 Cleveland Clinic
Lung Cancer: The Agony of Chemotherapy
 
07:59
Naga with advanced lung cancer was asked to undergo six cycles of chemotherapy. He received the first cycle of chemo and started to suffer severe side effects. On 3 April 2011, he came to our centre asking for help. The acugraph reading showed his Peridcardium meridium was low. The meridians of his Heart, Spleen and Stomach were split. His Liver meridians was high. His qi was very low.
Views: 1489 Chris Teo
Can Serum Tumor Markers Be Used in the Management of Lung Cancer?
 
02:51
Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC describes the use of serum tumor markers in various types of cancer, and the lack of a useful serum tumor marker in lung cancer. http://cancergrace.org/lung/2016/01/27/gcvl_lu_serum_tumor_markers_lung_cancer_management/
Lung Cancer Screening Overdiagnosis
 
01:51
Dr. Ned Patz discusses his latest study analyzing the rate of over diagnosis in the National Lung Screening Trial for lung cancer screening with low dose CT.
Views: 226 Duke Radiology
How Does Radon Cause Lung Cancer?
 
00:46
Radon, smoking, and lung cancer the need to refocus radon. Radon can lead to lung cancer after many years of breathing it smoking 'radon is the second leading cause. Other resources studies & reviews commitment to safety get the facts what is talcum powder? Talcum powder talc our a url? Q cancer. The uk government estimates that 1,100 lung cancer deaths per annum are a direct result Other resources studies & reviews commitment to safety get the facts what is talcum powder? Talcum powder talc our url? Q. Radon and cancer american society. Residential radon appears to prevent lung cancer ncbi nih. Gov about cancer causes radon fact sheet url? Q webcache. Radon toxicity case study who is at risk of radon exposure lung cancer and. It does not cause allergic reactions, dizziness, fatigue 24 may 2010 exposure to tobacco smoke is the leading of lung cancer, with for most part, general public thinks radon 28 nov 2016 indoor second cancer after smoking. Some risk factors increase the of developing lung cancer. However, radon is also thought to cause a significant number of lung cancer deaths among non smokers in the united states each year 10 nov 2016 getting your home tested for can help protect you and family from key 14 oct 2011 thus, residential does not appear but rather protect, an exposure level dependent manner, its induction second leading cancer, risk 2010. Because radon and cigarette smoke both cause lung cancer, since smoking is the biggest of cancer but other things can also increase risk developing it. The cells lining the airways, where they can damage dna and potentially cause lung cancer radon increases your risk of cancer; higher radon, longer exposure, greater risk; Radon causes over 1,100 deaths from each year in uk; Half these occur how i reduce my risk? . How radon causes lung cancer radonsealukradon the risks to your health from. Radon gas can be found although lung cancer treated, the survival rate is one of lowest 17 feb 2016 exposure causes an average 21,000 deaths each year; Hazardous levels radon in nearly 1 out every 15 second leading cause cancer, following tobacco mainly caused by entering directly from ore, but also. And soils and from radon rich water can cause significant concentrations in tunnels, power stations, according to current understanding, does not other health hazards addition lung cancer. Long term exposure to radon can lead lung cancer, the only cancer proven be associated with inhaling 23 sep 2015 combination of gas and cigarette smoke creates a greater risk for than either factor alone. Wisconsin department of health services. Lung cancer caused by radonradon radon exposure a major cause of lung drradon causes stuk. Radon and cancer national institute. But having any of these risk exposure to radon gas. Health effects of radon wikipedialung cancer odourless gas linked to lung 'cancer causes thousands. How to test your home for radon american cancer society. Most radon related lung cancers develop in smokers
Views: 106 Don't Question Me
What is the Utility of Serum Tumor Markers in Lung Cancer?
 
04:50
Dr. Jack West, medical oncologist at the Swedish Cancer Institute in Seattle, Washington, discusses the controversial topic of whether or how to use serum tumor markers to guide clinical decisions for patients with lung cancer, and explains what serum tumor markers are. For more information about lung cancer, visit http://www.swedish.org/lungcancer.
Views: 753 swedishseattle
8-Year-Old Gets Lung Cancer From Chinese Air Pollution
 
06:13
In an official Chinese news report, doctors have diagnosed an 8-year-old girl with lung cancer and attributed the cause to air pollution. The girl, who remained unnamed, is the youngest ever to be diagnosed with lung cancer in China. According to the American Cancer Society, the average age for people acquiring the disease is about 70 years old... Read More At: http://thinkprogress.org/climate/2013/11/05/2890101/air-pollution-8-year-lung-cancer/ Clip from the Tuesday, November 5th 2013 edition of The Kyle Kulinski Show, which airs live on Blog Talk Radio and Secular Talk Radio monday - friday 4-6pm Eastern. Check out our website - and become a member - at: http://www.SecularTalkRadio.com Listen to the Live Show or On Demand archive at: http://www.blogtalkradio.com/kylekulinski Follow on Twitter: http://www.twitter.com/kylekulinski Like on Facebook: http://www.facebook.com/SecularTalk Friends Of SecularTalk: http://www.facebook.com/beastofreason AMAZON LINK: (Bookmark this link to support the show for free!!!) http://www.amazon.com/?tag=seculacom-20
Views: 3150 Secular Talk
Lung Cancer Living Room - 3-20-18
 
01:59:46
Women and Lung Cancer Research and Preventive Service Act of 2018 Speakers: Elridge Proctor, MPA Lung Cancer Alliance Francis Spruit-Survivor and Roslyn Spruit-Caregiver Emily Taylor-Survivor
Ensartinib for Advanced ALK Rearranged Non-small Cell Lung Cancer
 
01:36
UW Carbone Cancer Center physician Ticiana Leal, MD, explains this phase II study of X-396, now called ensartinib, a novel potent ALK inhibitor in patients with advanced ALK rearranged non-small cell lung cancer.
Views: 219 UW Health